Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study
Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast.
For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Main Inclusion Criteria:
Main Exclusion Criteria:
Marietta, Wisconsin 53717, United States
Adelaide South Australia, 5000, Australia
Belo Horizonte - MG CEP, 30130100, Brazil
Botucatu - SP CEP, 16618000, Brazil
Curitiba-PR, 80060900, Brazil
Florianópolis-SC, 88040970, Brazil
Juiz de Fora-MG, 36036110, Brazil
Porto Alegre-RS, 90035003, Brazil
Porto Alegre-RS, 90610000, Brazil
Quadra 605 Brasilia - DF, Brazil
Recife - PE, Brazil
Rio de Janeiro-RJ, 21941590, Brazil
Santo André-SP, 9060650, Brazil
São Paulo-SP, 1221020, Brazil
São Paulo-SP, 4023062, Brazil
São Paulo-SP, 5403900, Brazil
Clermont-Ferrand Cedex1, 63003, France
Ferolles-Attily, 77150, France
Nyiregyháza, 4412, Hungary
Baillieston, Glasgow, G69 7AD, United Kingdom
Bath, Avon, BA2 3HT, United Kingdom
Co. Antrim, BT38 8TP, United Kingdom
County Antrim, BT37 9QN, United Kingdom
East Sussex, TN39 5HE, United Kingdom
East Sussex, TN40 1JJ, United Kingdom
Fife, KY12 8SJ, United Kingdom
Glengormley Newtownabbey, BT36 5EQ, United Kingdom
Southdown, Bath, BA2 1NH, United Kingdom
Sunbury on Thames, Middlesex, TW16 6RH, United Kingdom
Vale of Glamorgan, CF64 2XX, United Kingdom